The interesting question in a neurotechnology funding story is not only how much money moved. It is what the company intends to measure, who will use the result, and what evidence would make that measurement useful. Eye-tracking offers a concrete example of those questions.
What was announced
neuroClues announced a €10 million Series A led by Teampact Ventures, White Fund and the EIC Fund, with participation from existing backers. Its press release carries a March 31, 2026 dateline and was posted on April 10. This is a report of that announcement, not a newly announced September round. [1]
The company describes the financing as support for commercialization of its clinical eye-tracking platform. It separately reports €25 million in total capital raised, including additional non-dilutive funding. That total should not be mistaken for the size of this Series A. [1]
What the product is for
The company describes a device that records and analyzes eye movements during visual tasks. Its current website identifies the intended role as supporting the detection of visual-tracking impairments in people aged five and older. It also states that interpretation should be guided by the clinical question and the wider neurological examination. [2]
Those boundaries matter. A quantified measurement can contribute to an assessment without becoming an independent diagnosis. The product description is a manufacturer statement; this article does not validate its performance or establish that it can reliably identify a particular neurological disease.
The evidence to ask for next
For a clinical measurement tool, we would want to know whether results are repeatable, whether different operators obtain comparable measurements, and how performance changes across the populations in which the device is intended to be used. A clearly defined comparison standard matters more than an impressive-sounding biomarker label.
The next question is usefulness: does adding the information improve a decision clinicians actually need to make? A numerical output, a commercial deployment and a patient benefit are different milestones. Investment can help fund that work, but it does not substitute for the work itself.
Why it belongs in this publication
This story connects a visible behavior—moving the eyes—with the less visible problem of interpreting nervous-system function. That makes it worth following without turning a financing announcement into an endorsement. The right follow-up is a close look at relevant clinical studies and their limitations, not a repetition of investor enthusiasm.
Our reporting here is based on the company’s published announcement and product description. It is neither investment advice nor a recommendation to seek a test, and it makes no claim that a funding round proves clinical effectiveness.